双百口服液治疗初治继发性肺结核172例临床观察  

Clinical Observation of 172 Cases of Secondary Pulmonary Tuberculosis in the Early Treatment with Shuangbai Koufu Ye

作　　者：周杰[1] 王胜圣[1] 于春江 赵宏伟 

机构地区：[1]吉林省中医药科学院,吉林长春130021 [2]吉林一正药业集团有限公司,吉林四平136001

出　　处：《世界中西医结合杂志》2013年第8期784-786,789,共4页World Journal of Integrated Traditional and Western Medicine

基　　金：国家科技重大专项课题(2008ZX10005-010)

摘　　要：目的探讨双百口服液治疗气阴两虚型初治继发性肺结核的临床疗效及安全性。方法将324例气阴两虚型初治继发性肺结核患者随机分为两组,治疗组172例,对照组152例。两组均采用2HREZ/4HR化疗方案治疗,治疗组在化疗方案的基础上加用双百口服液,疗程为6个月。每月检查痰涂片、肝功能等指标,隔月复查胸部X线片,并进行中医证候评分。结果治疗1～6个月期间,两组痰菌转阴率比较,差异无统计学意义(P>0.05);两组患者肺部阴影明显吸收率及吸收率比较,差异有统计学意义(P<0.05);两组空洞闭合率比较,差异无统计学意义(P>0.05);两组愈显率和有效率比较,差异有统计学意义(P<0.01,P<0.05);两组毒副反应情况比较,差异有统计学意义(P<0.05)。结论双百口服液治疗气阴两虚型初治继发型肺结核临床疗效显著,且比较安全。Objective To explore the clinical therapeutic effect and safety of shuangbai koufu ye on the secondary pulmonary tuberculosis of qi and yin deficiency pattern in the early treatment.Methods Three hundred and twenty-four cases of secondary pulmonary tuberculosis of qi and yin deficiency pattern in the early treatment were randomized into a trial group（172 cases） and a control group（152 cases）.2HREZ /4HR chemotherapy was applied in the two groups.In the treatment group,on the basis of treatment as the trial group,shuangbai kofu ye was added.The duration of treatment was 6 months.The sputum smear and liver function were tested every month.The chest X-ray film was taken once every two months.The Chinese medicine syndrome score was evaluated.Results In the treatment of 1 ～ 6 months,the negative conversion ratio of sputum bacteria was not different in comparison between two groups statistically（P 0.05）.The differences in the apparent absorption rate of lung shadow and absorption rate were significant statistically in the patients between the two groups（P 0.05）.The cavity closure rate was not different significantly between the two groups（P 0.05）.The differences in the curative and effective rate and the effective rate were significant statistically between the two groups（P 0.01,P 0.05）.The difference in the toxic side reactions was significant statistically between the two groups（P 0.05）.Conclusion Shuangbai koufu ye achieves the significant clinical efficacy on secondary pulmonary tuberculosis of qi and yin deficiency pattern in the early treatment and it is the safe therapy.

关 键 词：双百口服液 气阴两虚证 初治 继发性肺结核 临床观察 

分 类 号：R521.5[医药卫生—内科学]